380844-24-6

Basic information

• Product Name: methyl 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzoate
• Synonyms: methyl 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzoate
• CAS NO: 380844-24-6
• Molecular Weight: 303.699
• Mol File: 380844-24-6.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: methyl 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzoate(380844-24-6)
• EPA Substance Registry System: methyl 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzoate(380844-24-6)

Safety Data

• Hazardous Substances Data: 380844-24-6(Hazardous Substances Data)

Upstream product

• 215659-03-3 methyl 5-hydroxy-4-methoxy-2-nitrobenzoate 
• 109-70-6 1.3-chlorobromopropane 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 929683-54-5 3-(3-chloropropoxy)-4-methoxybenzaldehyde 
• 621-59-0 isovanillin 
• 645-08-9 Isovanillic acid 
• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 380844-22-4 methyl 3-(3-chloropropoxy)-4-methoxybenzoate 

Downstream Products

• 214472-37-4 4-methoxy-5-(3-morpholinylpropoxy)-2-nitrobenzoic acid methyl ester 
• 1259017-55-4 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl 4-(bis(4-fluorophenyl)methyl)piperazine-1-carbodithioate 
• 1259017-73-6 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(3-chloropropoxy)-7-methoxyquina-zolin-4-amine 
• 1259017-72-5 N-(3-bromophenyl)-6-(3-chloropropoxy)-7-methoxyquinazolin-4-amine 
• 1259017-50-9 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl 4-methylpiperazine-1-carbodithioate 
• 1259017-48-5 3-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)propyl 4-methylpiperazine-1-carbodithioate 
• 1259017-46-3 3-(4-(3-bromophenylamino)-7-methoxyquinazolin-6-yloxy)propyl 4-methylpiperazine-1-carbodithioate 
• 1259017-51-0 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl piperazine-1-carbodithioate 
• 1259017-53-2 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl morpholine-4-carbodithioate 
• 1259017-54-3 3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)propyl thiomorpholine-4-carbodithioate 
• 1456070-16-8 C₂₃H₂₄ClFN₄O₄S 
• 1456070-17-9 C₂₁H₂₂ClFN₄O₃ 
• 1456070-18-0 C₂₂H₂₄ClFN₄O₃ 
• 1445860-68-3 4-(3'-chloro-4'-fluorophenylamino)-6-[3-(2-oxa-6-azaspiro[3.4]octane-6-yl)propoxy]-7-methoxyquinazoline 

Relevant articles and documents

PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ?-CELL PATHOGENESIS AND TREATING DIABETES

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and/or reversing, returning blood glucose concentration to a normal level in a diabetic.

Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines

On the basis of combination strategy, a novel series of EGFR inhibitors were designed and synthesized by combination of dithiocarbamic acid esters and 4-anilinoquinazolines. The effect of the synthesized compounds on cell proliferation was evaluated by MTT assay in three human cancer cell lines: MDA-MB-468, SK-BR-3 and HCT-116. Two compounds (11d and 11f) were found more potent against all three cell lines and five compounds (11a, 11d-11g) were found more potent against both MDA-MB-468 and SK-BR-3 than Lapatinib. SAR studies revealed that the substituents on C6 and C7 positions of quinazoline, the amine component of dithiocarbamate moiety and the linker greatly affected the activity. This work provides a promising new strategy for the preparation of potent tyrosine kinase inhibitors.

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors

Aryl phenyl ureas with a 4-quinazolinoxy substituent at the meta-position of the phenyl ring are potent inhibitors of mutant and wild type BRAF kinase. Compound 7 (1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy) phenyl)urea hydrochloride) exhibits good pharmacokinetic properties in rat and mouse and is efficacious in a mouse tumor xenograft model following oral dosing.